In Invitrogen’s first-quarter conference call, company executives said the company’s RNAi business, which comes from its November 2003 acquisition of Sequitur, is growing.
Although revenue growth was flat for the company’s core genomics business, “our RNAi business is going very strong,” CEO and President Greg Lucier said in the call Thursday. “We are really pleased with the overall Stealth RNAi business and that’s right on track in terms of its performance.”
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
